Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers

References

• Feizi S. Corneal endothelial cell dysfunction: etiologies and management. Ther Adv Ophthalmol. 2018 Dec 7;10:2515841418815802.
   Web of Science ®Google Scholar
• Bremond-Gignac D, Copin H, Benkhalifa M. Corneal epithelial stem cells for corneal injury. Expert Opin Biol Ther. 2018;18:997–1003.
   PubMed Web of Science ®Google Scholar
• Sridhar MS. Anatomy of cornea and ocular surface. Indian J Ophthalmol. 2018;66:190–194.
   PubMed Web of Science ®Google Scholar
• Ziaei M, Greene C, Green CR. Wound healing in the eye: therapeutic prospects. Adv Drug Deliv Rev. 2018;126:162–176.
   PubMed Web of Science ®Google Scholar
• Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol. 2014;28:168–172.
   PubMedGoogle Scholar
• Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571–579.
   PubMedGoogle Scholar
• Cochener B, Zagnoli C, Hugny-Larroque C, et al. Healing of resistant corneal neurotrophic ulcers using a matrix regenerating agent. J Fr Ophtalmol. 2019;42:159–165.
   PubMed Web of Science ®Google Scholar
• Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;66:107–131.
   PubMed Web of Science ®Google Scholar
• Sun Y-Z, Guo L, Zhang F-S. Curative effect assessment of bandage contact lens in neurogenic keratitis. Int J Ophthalmol. 2014;7:980–983.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Forbice E, Braga O, et al. Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies. Biomed Res Int. 2014;2014:826970.
   PubMed Web of Science ®Google Scholar
• Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467–1474.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Bruscolini A, Lambiase A. Cenegermin for the treatment of neurotrophic keratitis. Drugs Today. 2017;53:585–595.
   PubMed Web of Science ®Google Scholar
• Chebbi CK, Kichenin K, Amar N, et al. Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy. J Fr Ophtalmol. 2008;31:465–471.
   PubMed Web of Science ®Google Scholar
• Brignole-Baudouin F, Warnet JM, Barritault D, et al. RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies. J Fr Ophtalmol. 2013;36:740–747.
   PubMed Web of Science ®Google Scholar
• Aifa A, Gueudry J, Portmann A, et al. Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. Invest Ophthalmol Vis Sci. 2012;53:8181–8185.
   PubMed Web of Science ®Google Scholar
• Sosne G, Kleinman HK. Primary mechanisms of thymosin β4 repair activity in dry eye disorders and other tissue injuries. Invest Ophthalmol Vis Sci. 2015;56:5110–5117.
   PubMed Web of Science ®Google Scholar
• Elbadawy HM, Mirabelli P, Xeroudaki M, et al. Effect of connexin 43 inhibition by the mimetic peptide Gap27 on corneal wound healing, inflammation and neovascularization. Br J Pharmacol. 2016;173:2880–2893.
   PubMed Web of Science ®Google Scholar
• Ormonde S, Chou C-Y, Goold L, et al. Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular persistent epithelial defect wounds. J Membr Biol. 2012;245:381–388.
   PubMed Web of Science ®Google Scholar
• Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125:1332–1343.
   PubMed Web of Science ®Google Scholar
• Xie Y, Longo FM. Neurotrophin small-molecule mimetics. Prog Brain Res. 2000;128:333–347.
   PubMed Web of Science ®Google Scholar
• Timaru C-M, Stefan C, Iliescu DA, et al. Matrix regenerative therapy. Rom J Ophthalmol. 2017;61:2–10.
   PubMedGoogle Scholar
• Barritault D, Gilbert-Sirieix M, Rice KL, et al. RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Glycoconj J. 2017;34:325–338.
   PubMed Web of Science ®Google Scholar
• Fajnkuchen F, Barritault D, Giocanti-Aurégan A. Evaluation of a new matrix regenerating agent in patients with Sjögren syndrome and superficial ulcerative keratitis resistant to conventional therapy: a report of 3 cases. Medicine (Baltimore). 2018;97:e9935.
   PubMed Web of Science ®Google Scholar
• Cejkova J, Olmiere C, Cejka C, et al. The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage. Histol Histopathol. 2014;29:457–478.
   PubMed Web of Science ®Google Scholar
• Chappelet M-A, Bernheim D, Chiquet C, et al. Effect of a new matrix therapy agent in persistent epithelial defects after bacterial keratitis treated with topical fortified antibiotics. Cornea. 2017;36:1061–1068.
   PubMed Web of Science ®Google Scholar
• Guerra M, Marques S, Gil JQ, et al. Neurotrophic keratopathy: therapeutic approach using a novel matrix regenerating agent. J Ocul Pharmacol Ther. 2017;33:662–669.
   PubMed Web of Science ®Google Scholar
• Aynsley TR. THE USE OF INSULIN IN THE TREATMENT OF CORNEAL ULCERS. Br J Ophthalmol. 1945;29:361–363.
   PubMed Web of Science ®Google Scholar
• Wang AL, Weinlander E, Metcalf BM, et al. Use of topical insulin to treat refractory neurotrophic corneal ulcers. Cornea. 2017;36:1426–1428.
   PubMed Web of Science ®Google Scholar
• Fai S, Ahem A, Mustapha M, et al. Randomized controlled trial of topical insulin for healing corneal epithelial defects induced during vitreoretinal surgery in diabetics. Asia Pac J Ophthalmol (Phila). 2017;6:418–424.
   PubMed Web of Science ®Google Scholar
• Yanai R, Nishida T, Chikama T-I, et al. Potential new modes of treatment of neurotrophic keratopathy. Cornea. 2015;34(Suppl 11):S121–127.
   PubMed Web of Science ®Google Scholar
• Yamada N, Matsuda R, Morishige N, et al. Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol. 2008;92:896–900.
   PubMed Web of Science ®Google Scholar
• Crockford D, Turjman N, Allan C, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179–189.
   PubMed Web of Science ®Google Scholar
• Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74:293–299.
   PubMed Web of Science ®Google Scholar
• Dunn SP, Heidemann DG, Chow CYC, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Ann N Y Acad Sci. 2010;1194:199–206.
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzábal F, Riestra A, et al. Galenic validation of plasma rich in growth factors eye drops. Farm Hosp. 2019;43:45–49.
   PubMed Web of Science ®Google Scholar
• Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et al. Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops. Int Ophthalmol. 2018;38:1193–1204.
   PubMed Web of Science ®Google Scholar
• Poon AC, Geerling G, Dart JK, et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001;85:1188–1197.
   PubMed Web of Science ®Google Scholar
• Wawrzynski J, Mukherjee H, Moore J, et al. Fingerprick autologous blood for dry eyes and persistent epithelial defects. Eye (Lond). 2016;30:635–636.
   PubMed Web of Science ®Google Scholar